A detailed history of Tri Locum Partners LP transactions in Verona Pharma PLC stock. As of the latest transaction made, Tri Locum Partners LP holds 593,980 shares of VRNA stock, worth $21.2 Million. This represents 4.56% of its overall portfolio holdings.

Number of Shares
593,980
Holding current value
$21.2 Million
% of portfolio
4.56%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.46 - $30.16 $9.18 Million - $17.9 Million
593,980 New
593,980 $17.1 Million
Q4 2023

Feb 14, 2024

SELL
$11.94 - $20.47 $298,070 - $511,013
-24,964 Reduced 7.85%
293,112 $5.83 Million
Q3 2023

Nov 14, 2023

BUY
$16.3 - $22.09 $2.72 Million - $3.69 Million
166,882 Added 110.38%
318,076 $5.18 Million
Q2 2023

Aug 14, 2023

BUY
$19.41 - $23.43 $1.04 Million - $1.25 Million
53,380 Added 54.57%
151,194 $3.2 Million
Q1 2023

May 15, 2023

BUY
$18.06 - $25.27 $1.77 Million - $2.47 Million
97,814 New
97,814 $1.96 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.17B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Tri Locum Partners LP Portfolio

Follow Tri Locum Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.